Stiris Research Inc. hits corporate target of First Patient treated on US pancreatic cancer program
Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces successfully achieving the Australian biotech’s corporate milestone of First Patient implanted in their US pancreatic cancer study.
“Stiris is pleased to announce that the first patient has received a successful one-time implantation of Investigational Product into a pancreatic tumour at a leading cancer center in the United States. This premier cancer center was the first site to enroll a subject into the study. Usually, locally advanced pancreatic cancer (LAPC) patients are treated with a combination of chemotherapy and radiation treatments and this treatment allows patients the freedom of not having to have weekly radiation therapy. As a result, this treatment regimen reduces the burden on this very ill patient population, giving them more time to be at home, with family and friends,” said V Zumbrunn, US Project Manager, Stiris Research.
Pancreatic cancer is the fourth highest cause of cancer death and is expected to be the second highest cause of cancer death by 2030 in Western countries (World Journal of Clinical Oncology, Vol 7 Issue 1 pp 27-43). Globally, 277,000 new cases of pancreatic cancer are diagnosed annually with the 5-year overall survival rate increasing only by 1% (from 5% to 6%) in the past three decades although there have been improvements in detection (Drug Design, Development and Therapy Vol 9 pp 3529-3545).
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.
For more information, please contact: